Aljian Capital Management LLC Raises Stock Holdings in Stryker Co. (NYSE:SYK)

Aljian Capital Management LLC boosted its holdings in Stryker Co. (NYSE:SYK) by 6.1% during the 3rd quarter, Holdings Channel reports. The firm owned 12,605 shares of the medical technology company’s stock after acquiring an additional 722 shares during the period. Stryker makes up about 1.1% of Aljian Capital Management LLC’s investment portfolio, making the stock its 13th largest holding. Aljian Capital Management LLC’s holdings in Stryker were worth $4,554,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of SYK. Centennial Bank AR raised its holdings in shares of Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares during the period. HBW Advisory Services LLC bought a new stake in shares of Stryker in the third quarter valued at $42,000. Hara Capital LLC purchased a new position in shares of Stryker during the 3rd quarter valued at $42,000. Grove Bank & Trust grew its stake in shares of Stryker by 84.8% during the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after acquiring an additional 56 shares during the period. Finally, DT Investment Partners LLC increased its holdings in Stryker by 114.3% in the 3rd quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company’s stock worth $49,000 after acquiring an additional 72 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Viju Menon sold 600 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. The trade was a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 67,381 shares of company stock worth $24,825,275 in the last ninety days. 5.50% of the stock is owned by company insiders.

Stryker Stock Up 1.8 %

Shares of SYK opened at $390.08 on Monday. The firm has a market cap of $148.71 billion, a P/E ratio of 41.81, a P/E/G ratio of 2.94 and a beta of 0.91. Stryker Co. has a 1 year low of $282.35 and a 1 year high of $392.70. The stock has a 50 day simple moving average of $364.07 and a two-hundred day simple moving average of $347.54. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm’s revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.46 EPS. On average, analysts forecast that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SYK has been the topic of several recent research reports. Barclays upped their price objective on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Stifel Nicolaus cut their price objective on shares of Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. StockNews.com raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Thursday. Robert W. Baird raised their price target on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Finally, Wolfe Research started coverage on shares of Stryker in a report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $393.65.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.